Surefire Medical, Inc., a Westminster, Colo.-based developer of site-specific delivery devices for the Interventional Oncology market, held the first closing of a $12.8 M Series D financing round.
The round was led by ORI Healthcare Fund (ORI Fund) with continued support from previous funders.
The company intends to use the funds to
– expand sales and marketing in the U.S. and Europe
– initiate sales and clinical trials in the multibillion dollar China market
– complete the 170-patient randomized controlled QED clinical trial (NCT02748161), and
– pursue opportunities in the $66B immunotherapy market, focusing on site-specific delivery to solid tumors.
Led by President and CEO James Chomas, Surefire Medical develops, manufactures and markets targeted delivery devices for the Interventional Oncology markets. Its core technology consists of a microcatheter with an expandable tip that improves tumor uptake while protecting healthy tissue.